CD85j (ILT2) Antibodies

CD85j, also called ILT2, is a member of the immunoglobulin (Ig)-like transcripts (ILT) family of genes located on human chromosome 19 (the numerical subclassification refers to the members in the order of the gene on the chromosome). It is a 110-kDa transmembrane glycoprotein. ILT2 receptor is a NK receptor involved in inhibition of NK and T cells cytolytic activity and cytokine production. ILT2 is also known as leucocyte Ig-like receptor (LIR)-1 and monocyte / macrophage Ig-like receptor (MIR)-7. The protein has 4 extracellular Ig-SF domains, and 4 cytoplasmic ITIM motifs in the cytoplasmic tail. Both myeloid and lymphoid cells express ILT2. Among lymphoid cells, NK cells, T cell subsets and all peripheral B cells express ILT2. It is also expressed on monocytes, macrophages, and dendritic cells. Ligands for CD85j are non-classical class I HLA-G molecules, certain alleles of HLA-A and -B loci and the human cytomegalovirus gene product, UL18, a viral homolog of HLA class I molecules. The inhibitory function of CD85j has been explored mainly in NK and T cells. In NK cells, ILT2 inhibits the cytolysis of HLA-Class I-positive target cells. In T cells, ILT2 inhibits both signaling and cellular events that control the activation of T cells.


Clone: HP-F1 Isotype: IgG1 Mouse

Explore CD85j (ILT2) Antibodies

Content and Resources

Immunophenotyping reference table - For haematopoietic malignancies Poster - Immunophenotyping reference table - For haematopoietic malignancies
How do I preserve sensitivity? Poster - How to preserve sensitivity
IVDR: a new era for In-Vitro Diagnostic Medical Devices BEC Marseille IVDR team, in the framework of the IVDR Global program, has established and deployed a robust project plan to fulfill IVDR requirements of more than 230 IVD CE marked products for May 2022
Mesenchymal Stem Cells (MSC) - Conjugated Antibody Portfolio CD133-APC completed conjugated antibody portfolio for basic mesenchymal progenitor cells studies